Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1403026

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1403026

Lab Automation In Genomics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

Lab Automation In Genomics - Market - IMG1

The Global Lab Automation in the Genomics market is valued at USD 2.12 billion in 2024. It is expected to grow to USD 3.81 billion, registering a CAGR of 12.43 percent during the forecast period. There has been a significant improvement in understanding genome sequencing in terms of data analytics advances that reveal unknown correlations, hidden patterns, and other insights, especially when testing data sets on a large scale. This is due to technological advancements and increasing computational capacities driving the market.

Key Highlights

  • The development of genomics, which uses the availability of whole DNA sequences for entire organisms, is due to the innovative work of a few genomics giants and the more recent next-generation sequencing technology.
  • The speed, volume, and price of genome sequencing have all dramatically increased because of the development of next-generation sequence technologies. Additionally, hundreds of life science databases and programs that promote scientific study have been made possible because of advancements in bioinformatics. These databases make it simple to search, contrast, and analyze the information that is organized and kept there.
  • Furthermore, significant medical advancements are occurring quickly, mostly due to recent improvements in genomic analysis. DNA sequence analysis clarifies how genetic diversity causes disease and ultimately results in novel treatments. Additionally, laboratory automation has opened space for innovative flexibility, increased throughput, and cost-effective solutions. It allows for quick handling and enables the process to be sped up without worrying about accuracy and dependability. Due to the low cost of genotyping and DNA sequencing, the expansion rate is strong.
  • Genetic testing start-ups have been springing up like daisies due to improvements in DNA sequencing technology that have made it more affordable and widely available. However, the knowledge of whole genomes has made functional genomics viable, particularly interested in gene expression patterns under various situations, making it possible for genome sequencing programs to increase rapidly in breadth and speed. The most important tools, in this case, are microarrays and bioinformatics.
  • Nucleic acid isolation, RNAi screening, CRISPR analysis, PCR, and gene expression analysis are just a few of the genomics applications that use automation. Laboratory automation players/vendors are developing tools to meet these application requirements. For example, Tecan Group's new "Fluent Automation Workstation" platform incorporates a variety of capabilities to simplify day-to-day laboratory automation and increase workflow productivity. During a run, the system reacts dynamically, adjusting based on actual times to maintain continuous optimal throughput, all of which are visible in real-time via an easy-to-understand Gantt chart.
  • The companies are developing new products or incorporating new features in the existing products to meet the needs of the customer. For instance, in May 2023, opentrons, a lab automation solution provider, announced the launch of an Opentrons Flex robot, a liquid-handling lab robot. Flex Robot is compatible with artificial intelligence tools.
  • The cost is the major concern in lab automation in the genomics market. The initial setup cost is high, so several developing countries focus on the adoption of cost-effective lab automation systems such as refurbished lab automation. Also, declining consumer spending on buying new and costly equipment due to increasing interest rates and economic downturns restrict market growth.
  • The COVID-19 pandemic highlighted the difficulties of high-throughput molecular testing, necessitating a more integrated method to satisfy workload demands without sacrificing results quality, and various partnerships were witnessed in the market focusing on molecular testing. For instance, in February 2021, Tecan, a products, services, and solutions provider for lab processes and medical procedures, and UgenTec, a laboratory software company, announced a partnership to produce fully integrated sample-to-result PCR workflow solutions. Tecan's liquid handling and automation capabilities will be combined with UgenTec's FastFindersoftware, combining end-to-end automation with extensive data analysis and workflow tools to provide high-throughput molecular testing solutions.

Lab Automation In Genomics Market Trends

Automated Liquid Handlers to Witness High Growth

  • In the genomics lab, cross-contamination is a significant issue that can be prevented by employing automated systems to manage the reagents and reaction mixtures. It is thought that eliminating human intervention leads to more consistency. Numerous technological developments in the plastics molding industry have decreased the number of chemicals needed and made it easy to handle smaller volumes of liquid. These developments have made it easier to create micro- and nanoliter plates that can work with automated liquid-handling machinery.
  • Industry innovators have established the standard to create automated liquid handlers. To boost process productivity, these businesses consistently invest in designing quality products. As an illustration, Agilent's adaptable and space-saving automated liquid handling systems allow for streamlined sample preparation with consistently high accuracy. While retaining repeatability, automation enables labs to run more samples and free up manual labor.
  • Additionally, the quick expansion of several clinical and pre-clinical trials across the globe, mostly in the US, has made the requirement for speed in sample analysis essential. The machines operate nonstop in clinical research and require sizable personnel to maintain proper operation. Additionally, the demand for early treatments and diagnostics grows as new diseases are discovered and old ones spread quickly. This is anticipated to accelerate the adoption of automated liquid handlers by raising the rate at which clinical diagnostic applications are made.
  • Automated liquid handling robots disperse and sample liquids in tubes or wells and are frequently integrated as mechanical injection modules as the front end of liquid chromatographic systems. This kind of equipment can also include automated pipetting systems and microplate washers. These essential labor-saving tools provide accurate sample preparation for various bioassays, liquid or powder weighing, sample preparation, and high throughput screening/sequencing (HTC).
  • The life science industry, in terms of automated liquid handlers, automated plate handlers, and robotic arms, among others, has had the third-highest growth in industrial robots, according to the Robotic Industries Association, to fulfill the demand.
Lab Automation In Genomics - Market - IMG2

North America Occupies the Largest Market Share

  • North America has been a pioneer in clinical research for years. This region is home to some of the major pharmaceutical companies, like Pfizer, Novartis, GlaxoSmithKline, J&J, and Novartis. The region also has the highest concentration of contract research organizations (CROs). Some of the significant CROs are Laboratory Corp. of America Holdings, IQVIA, Syneos Health, and Parexel International Corp.
  • Owing to the presence of all the major players in the industry and stringent FDA regulations, the market is very competitive in the region. To gain an advantage over competitors, the genomics research organizations in the region are increasingly adopting robotics and automation in labs.
  • The genomic industry, especially in the United States, is still in its growing phase and is expected to grow at a fast pace over the coming years. The availability of new genome sequencing technologies, well-established healthcare infrastructure, and the increasing geriatric population are significant contributing factors toward the revenue growth of the market.
  • In the United States, the need to accommodate growth and the drive to boost efficiency are priming blood centers to acquire fully automated walkaway systems, either to perform types and screens or to test specimens for infectious diseases or both.
  • The US genomic industry is expected to grow at a fast pace over the coming years. The availability of new genome sequencing technologies, well-established healthcare infrastructure, and the increasing geriatric population are significant contributing factors toward revenue growth of the market. Additionally, the demand for precision medicines is rising in the country.

Lab Automation In Genomics Industry Overview

Lab automation in the genomics market is moderately competitive, owing to many small and big players exporting products to many countries. The key strategies adopted by the major players are technological advancement in development, partnerships, and mergers and acquisitions. Some of the major players in the market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers, Danaher Corporation, PerkinElmer, and others.

In January 2023, Becton, Dickinson, and Company (BD) introduced a new lab automation solution - 'the third-generation BD Kiestra Total Lab Automation System' for microbiology laboratories. The new automated robotic track system will assist in streamlining workflow and optimizing lab space. It is used with the BD Kiestra microbiology laboratory solution that automates lab specimen processing.

In February 2023, Automata, a laboratory automation solution provider, announced a business expansion in the United States as it will likely help the United States life science industry to save lab spaces with automation. With Automata's technology, the United States life sciences industry will increase output and cut workflow times by up to 50%, increase existing lab space, and save scientists time to work on innovative research.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 47213

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Supply Chain Analysis
  • 4.3 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Buyers
    • 4.3.2 Bargaining Power of Suppliers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products
    • 4.3.5 Intensity of Competitive Rivalry
  • 4.4 Assessment of the COVID-19 Impact on the Industry

5 MARKET DYNAMICS

  • 5.1 Market Restraints
    • 5.1.1 Growing Trend of Digital Transformation for Laboratories with IoT
    • 5.1.2 Effective Management of the Huge Amount of Data Generated
  • 5.2 Market Challenges
    • 5.2.1 Expensive Initial Setup

6 MARKET SEGMENTATION

  • 6.1 By Equipment
    • 6.1.1 Automated Liquid Handlers
    • 6.1.2 Automated Plate Handlers
    • 6.1.3 Robotic Arms
    • 6.1.4 Automated Storage and Retrieval Systems (AS/RS)
    • 6.1.5 Vision Systems
  • 6.2 By Geography
    • 6.2.1 North America
    • 6.2.2 Europe
    • 6.2.3 Asia-Pacific
    • 6.2.4 Rest of the World

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Thermo Fisher Scientific Inc.
    • 7.1.2 Danaher Corporation / Beckman Coulter
    • 7.1.3 Hudson Robotics Inc.
    • 7.1.4 Becton, Dickinson and Company
    • 7.1.5 Synchron Lab Automation
    • 7.1.6 Agilent Technologies Inc.
    • 7.1.7 Siemens Healthineers AG
    • 7.1.8 Tecan Group Ltd.
    • 7.1.9 Perkinelmer Inc.
    • 7.1.10 Eli Lilly and Company
    • 7.1.11 F. Hoffmann-La Roche Ltd.

8 INVESTMENT ANALYSIS

9 FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!